false
0000888491
0000888491
2025-11-03
2025-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 3, 2025
OMEGA HEALTHCARE INVESTORS, INC.
(Exact name of registrant as specified in
its charter)
| Maryland |
1-11316 |
38-3041398 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
303 International Circle
Suite 200
Hunt Valley, Maryland 21030
(Address of principal executive offices
/ Zip Code)
(410) 427-1700
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act. |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities registered pursuant to Section
12(b) of the Securities Exchange Act of 1934:
| |
|
|
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, $.10 par value |
OHI |
New York Stock Exchange |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On November 3, 2025, Omega
Healthcare Investors, Inc. (the “Company”) entered into an “at-the-market” equity offering sales agreement
(the “Sales Agreement”) with each of the institutions named therein (or certain of their respective affiliates) in
their capacity as Sales Agents, as Forward Sellers and/or as Forward Purchasers, in each case as described below, relating to (i) the
issuance and sale by the Company to or through the Sales Agents, from time to time, of shares (the “Issuance Shares”)
of the Company’s common stock, par value $0.10 per share (“Common Stock”), and (ii) the sale by the Forward Sellers,
as agents on behalf of the Forward Purchasers, of Common Stock (the “Forward Shares” and, together with the Issuance
Shares, the “Securities”), with the Securities to be sold under the Sales Agreement not to exceed an aggregate gross
sales price of $2,000,000,000, and in connection therewith, on November 3, 2025, terminated its prior “at the market” equity
offering sales agreement dated September 6, 2024. We refer to these entities, when acting in their capacity as sales agents for the Company,
individually as a “Sales Agent” and collectively as the “Sales Agents,” when acting in their capacity
as counterparties to forward sale agreements, individually as a “Forward Purchaser” and collectively as the “Forward
Purchasers,” and when acting in their capacity as agents for the Forward Purchasers, individually as a “Forward Seller”
and collectively as the “Forward Sellers.”
Pursuant to the Sales Agreement,
the Company may enter into one or more forward sale agreements with one or more of the Forward Purchasers. In connection with each such
forward sale agreement, the relevant Forward Purchaser will, at the Company’s request, use commercially reasonable efforts to borrow
from third parties and, through the relevant Forward Seller, sell a number of Forward Shares equal to the number of shares of Common Stock
underlying such forward sale agreement.
The sales, if any, of the
Issuance Shares will be made through the Sales Agents acting as sales agents for the Company or directly to the Sales Agents acting as
principals. The sales, if any, of the Forward Shares will be made through the Forward Sellers, acting as agents for the applicable Forward
Purchasers. The sales, if any, of the Securities will be made by means of ordinary brokers’ transactions on the New York Stock Exchange,
by means of negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market
prices or at negotiated prices, or any other method permitted by applicable law. The Company has no obligation to sell any of the Securities
under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement.
Under the terms of the Sales
Agreement, Issuance Shares sold directly to the Sales Agents as principals for their own accounts will be sold at prices agreed upon at
the time of sale. If the Company sells Issuance Shares to any Sales Agent as principal, it will enter into a separate terms agreement
with such Sales Agent. Actual sales will depend on a variety of factors to be determined by the Company from time to time.
The Sales Agreement provides
that each Sales Agent will be entitled to compensation that will not exceed 2.0% of the gross sales price per share of all Issuance Shares
sold through it as Sales Agent. The Sales Agreement also provides that a Forward Seller will be entitled to commissions at a mutually
agreed rate that will not exceed 2.0% of the gross sales price of all borrowed shares of the Common Stock sold by the applicable Forward
Seller, which commissions will be in the form of a reduced initial forward sale price under the related forward sale agreement with the
related Forward Purchaser.
The foregoing description
of the Sales Agreement is a summary and is qualified in its entirety by reference to the Sales Agreement, which is filed as Exhibit 1.1
to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the form of forward sales agreement
is qualified in its entirety by reference to the form of forward sales agreement, which is filed as Annex 2 to Exhibit 1.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Although the Company expects
to physically settle any forward sale agreement into which it enters (by the delivery of shares of the Common Stock) and receive proceeds
from the sale of those shares of Common Stock upon one or more forward settlement dates no later than the date that is two years from
entry into the applicable forward sale agreement, the Company may elect to cash settle or net share settle all or a portion of its obligations
under any forward sale agreement. If the Company elects to cash settle any forward sale agreement, it may not receive any proceeds, and
it may owe cash to the relevant Forward Purchaser in certain circumstances. If the Company elects to net share settle any forward sale
agreement, it will not receive any proceeds, and it may owe shares of Common Stock to the relevant Forward Purchaser in certain circumstances.
Any forward sale agreement is subject to early termination or settlement under certain circumstances.
Certain of the Sale Agents,
the Forward Sellers, the Forward Purchasers and/or their respective affiliates have engaged in, and/or may in the future engage in, investment
banking, commercial banking, financial advisory and/or other commercial dealings in the ordinary course of business with the Company and/or
the Company’s subsidiaries, for which they have received and/or in the future may receive fees and commissions for these transactions
or services.
The Sales Agents under the
Sales Agreement are:
| Wells Fargo Securities, LLC |
Berenberg Capital Markets LLC |
BofA Securities, Inc. |
| BMO Capital Markets Corp. |
BNP Paribas Securities Corp. |
Citizens JMP Securities, LLC |
| Crédit Agricole Securities (USA) Inc. |
Huntington Securities, Inc. |
J.P. Morgan Securities LLC |
| Jefferies LLC |
KeyBanc Capital Markets Inc. |
M&T Securities, Inc. |
| Mizuho Securities USA LLC |
Morgan Stanley & Co. LLC |
MUFG Securities Americas Inc. |
| Raymond James & Associates, Inc. |
RBC Capital Markets, LLC |
Regions Securities LLC |
|
Robert W. Baird & Co. Incorporated
Truist Securities, Inc. |
Scotia Capital (USA) Inc. |
Stifel, Nicolaus & Company, Incorporated |
The Forward Purchasers under
the Sales Agreement are:
| Wells Fargo Bank, National Association |
Bank of America, N.A. |
Bank of Montreal |
| BNP PARIBAS |
Citizens JMP Securities, LLC |
Crédit Agricole Corporate and Investment Bank |
| Huntington Securities, Inc. |
Jefferies LLC |
JPMorgan Chase Bank, National Association |
| KeyBanc Capital Markets Inc. |
Mizuho Markets Americas LLC |
Morgan Stanley & Co. LLC |
| MUFG Securities EMEA plc |
Raymond James & Associates, Inc. |
Regions Securities LLC |
|
Robert W. Baird & Co. Incorporated
The Bank of Nova Scotia |
Royal Bank of Canada
Truist Bank |
Stifel, Nicolaus & Company, Incorporated
|
The Securities will be offered
and sold pursuant to an automatic shelf registration statement on Form S-3 Registration Statement (No. 333-277916). The Company filed
a prospectus supplement, dated November 3, 2025, with the Securities and Exchange Commission in connection with the offer, issuance and
sale of the Securities.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits. The following
exhibits are being filed herewith:
| No. |
|
Description |
| 1.1 |
|
At-the-Market Equity Offering Sales Agreement, dated November 3, 2025, among the Company, the Sales Agents, the Forward Sellers and the Forward Purchasers. |
| 5.1 |
|
Opinion of Shapiro Sher Guinot & Sandler, P.A. |
| 8.1 |
|
Tax Opinion of Bryan Cave Leighton Paisner LLP |
| 23.1 |
|
Consent of Shapiro Sher Guinot & Sandler, P.A. (Included in Exhibit 5.1). |
| 23.2 |
|
Consent of Bryan Cave Leighton Paisner LLP (Included in Exhibit 8.1). |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
OMEGA HEALTHCARE INVESTORS,
INC. |
| |
|
|
| Dated: November 3, 2025 |
By: |
/s/ Robert O. Stephenson |
| |
|
Robert O. Stephenson |
| |
|
Chief Financial Officer, Treasurer and Assistant Secretary |
